Seattle Genetics Stocks ListRelated Stock Lists: Cancer Medicine Monoclonal Antibodies Antibody Drug Conjugates Biopharmaceutical Biotechnology Clinical Medicine Treatment Of Cancer Cancer Treatments Lymphoma Solid Tumors Acute Myeloid Leukemia Antibodies Camidanlumab Tesirine Cd30 Chemical Compounds Chronic Lymphocytic Leukemia Drugs Head And Neck Cancer Hematologic Disorders
|2020-07-02||AVEO||Narrow Range Bar||Range Contraction|
|2020-07-02||CTIC||1,2,3 Pullback Bullish||Bullish Swing Setup|
|2020-07-02||CTIC||Crossed Above 20 DMA||Bullish|
|2020-07-02||CTIC||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2020-07-02||CTIC||Boomer Buy Setup||Bullish Swing Setup|
|2020-07-02||MEIP||Fell Below 20 DMA||Bearish|
|2020-07-02||MEIP||50 DMA Support||Bullish|
|2020-07-02||XCUR||Crossed Above 200 DMA||Bullish|
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The companys' flagship product Adcetris (Brentuximab vedotin) is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.
In January 2018, the business announced it would acquire Cascadian Therapeutics for $614 million.